MX344329B - Formulación de una combinación de dronedarona y ranolazina para la manufactura de un medicamento para tratar fibrilación atrial. - Google Patents

Formulación de una combinación de dronedarona y ranolazina para la manufactura de un medicamento para tratar fibrilación atrial.

Info

Publication number
MX344329B
MX344329B MX2014002642A MX2014002642A MX344329B MX 344329 B MX344329 B MX 344329B MX 2014002642 A MX2014002642 A MX 2014002642A MX 2014002642 A MX2014002642 A MX 2014002642A MX 344329 B MX344329 B MX 344329B
Authority
MX
Mexico
Prior art keywords
atrial fibrillation
treating atrial
salts
atrial
pharmaceutically acceptable
Prior art date
Application number
MX2014002642A
Other languages
English (en)
Inventor
Zeng Dewan
Shryock John
Belardinelli Luiz
Antzelevitch Charles
Burashnikov Alexander
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX344329(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX344329B publication Critical patent/MX344329B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica que comprende dronedarona o una sal farmacéuticamente aceptable de la misma, ranolazina, y un transportador o diluyente farmacéuticamente aceptable.
MX2014002642A 2009-12-21 2010-12-20 Formulación de una combinación de dronedarona y ranolazina para la manufactura de un medicamento para tratar fibrilación atrial. MX344329B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21
PCT/US2010/061257 WO2011084733A1 (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Publications (1)

Publication Number Publication Date
MX344329B true MX344329B (es) 2016-12-13

Family

ID=43736345

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012007052A MX2012007052A (es) 2009-12-21 2010-12-20 Metodo para tratar fibrilacion atrial.
MX2014002642A MX344329B (es) 2009-12-21 2010-12-20 Formulación de una combinación de dronedarona y ranolazina para la manufactura de un medicamento para tratar fibrilación atrial.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012007052A MX2012007052A (es) 2009-12-21 2010-12-20 Metodo para tratar fibrilacion atrial.

Country Status (36)

Country Link
US (3) US8513254B2 (es)
EP (2) EP2749282B1 (es)
JP (2) JP5723889B2 (es)
KR (2) KR20160108611A (es)
CN (3) CN102665713B (es)
AP (1) AP3536A (es)
AR (1) AR079552A1 (es)
AU (1) AU2010339753B2 (es)
BR (1) BR112012015499A2 (es)
CA (1) CA2784028C (es)
CL (1) CL2012001597A1 (es)
CR (1) CR20120353A (es)
CY (1) CY1116511T1 (es)
DK (1) DK2515900T3 (es)
EA (2) EA201691336A1 (es)
EC (1) ECSP12012004A (es)
ES (2) ES2540093T3 (es)
HR (1) HRP20150644T1 (es)
HU (1) HUE026916T2 (es)
IL (1) IL220152A (es)
ME (1) ME02179B (es)
MX (2) MX2012007052A (es)
NO (1) NO2749282T3 (es)
NZ (2) NZ600718A (es)
PE (1) PE20121520A1 (es)
PL (2) PL2515900T3 (es)
PT (2) PT2515900E (es)
RS (1) RS54118B1 (es)
SG (3) SG181541A1 (es)
SI (2) SI2749282T1 (es)
SM (1) SMT201500171B (es)
TW (1) TWI508726B (es)
UA (1) UA109887C2 (es)
UY (1) UY33119A (es)
WO (1) WO2011084733A1 (es)
ZA (1) ZA201204608B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486712C (en) 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
ME02847B (me) 2009-07-27 2018-01-20 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
CN104873389B (zh) 2009-07-29 2017-12-05 Icu医学有限公司 流体传输装置及使用方法
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
ES2648820T3 (es) 2011-05-10 2018-01-08 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de los canales de sodio
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
WO2013112932A1 (en) * 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US20140364417A1 (en) * 2013-05-03 2014-12-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
KR20160027078A (ko) * 2013-08-02 2016-03-09 길리애드 사이언시즈, 인코포레이티드 라놀라진 및 드로네다론의 제약 조성물
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
EP3083608B1 (en) 2013-12-19 2018-07-18 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
CA3103522C (en) * 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
EP3914709A4 (en) * 2019-01-24 2023-05-03 Northwestern University Gene therapy treatment of atrial fibrillation
US11712188B2 (en) * 2019-05-07 2023-08-01 Medtronic, Inc. Posterior left bundle branch engagement
IL290088B2 (en) 2019-08-01 2023-10-01 Incarda Therapeutics Inc A pharmaceutical preparation containing flacainide, cyclodextrin and acid, a dosage unit of the preparation and a kit containing the preparation
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ATE218344T1 (de) 1989-06-23 2002-06-15 Syntex Llc Ranolazin und verwandte piperazine zur behandlung von schockzuständen
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US20020042405A1 (en) * 2000-07-27 2002-04-11 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
EP1347756B1 (en) 2000-12-27 2006-03-08 Genzyme Corporation Controlled release of anti-arrhythmic agents from a biodegradable hydrogel for local application to the heart
WO2003009839A1 (en) * 2001-07-20 2003-02-06 Karo Bio Ab Benzofuranes and their use in the treatment of atrial fibrillation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
WO2006074398A2 (en) 2005-01-06 2006-07-13 Cv Therapeutics, Inc. Sustained release pharmaceutical formulations comprising ranolazine
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
EP2117508A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Intravenous solutions comprising ranolazine
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
US20100056536A1 (en) 2008-09-04 2010-03-04 Charles Antzelevitch Method of treating atrial fibrillation

Also Published As

Publication number Publication date
EA201290451A1 (ru) 2013-01-30
US20110183990A1 (en) 2011-07-28
CN104688739A (zh) 2015-06-10
NZ600718A (en) 2014-08-29
EP2749282A1 (en) 2014-07-02
KR20160108611A (ko) 2016-09-19
TWI508726B (zh) 2015-11-21
ZA201204608B (en) 2013-02-27
CA2784028C (en) 2016-08-23
AR079552A1 (es) 2012-02-01
ME02179B (me) 2015-10-20
SMT201500171B (it) 2015-09-07
EA201691336A1 (ru) 2017-05-31
MX2012007052A (es) 2012-07-30
US20130317038A1 (en) 2013-11-28
PT2749282T (pt) 2017-11-15
KR20120107995A (ko) 2012-10-04
CL2012001597A1 (es) 2013-06-28
CR20120353A (es) 2014-10-07
PL2515900T3 (pl) 2015-10-30
US8513254B2 (en) 2013-08-20
IL220152A0 (en) 2012-07-31
SG181541A1 (en) 2012-07-30
CN102665713B (zh) 2015-02-18
SG10201710751TA (en) 2018-02-27
HRP20150644T1 (hr) 2015-07-31
CN102665713A (zh) 2012-09-12
ES2646603T3 (es) 2017-12-14
PT2515900E (pt) 2015-07-30
ES2540093T3 (es) 2015-07-08
DK2515900T3 (en) 2015-07-27
ECSP12012004A (es) 2012-08-31
TW201136586A (en) 2011-11-01
PE20121520A1 (es) 2012-11-26
CA2784028A1 (en) 2011-07-14
NZ627181A (en) 2016-02-26
JP2015057449A (ja) 2015-03-26
HUE026916T2 (en) 2016-08-29
HK1170675A1 (en) 2013-03-08
AU2010339753A1 (en) 2012-07-12
NO2749282T3 (es) 2018-01-06
RS54118B1 (sr) 2015-12-31
US9056108B2 (en) 2015-06-16
EP2515900B1 (en) 2015-04-29
EP2515900A1 (en) 2012-10-31
SG10201408528RA (en) 2015-04-29
PL2749282T3 (pl) 2018-01-31
JP2013515007A (ja) 2013-05-02
IL220152A (en) 2016-11-30
EA025445B1 (ru) 2016-12-30
AU2010339753B2 (en) 2015-01-22
US20140323493A1 (en) 2014-10-30
CY1116511T1 (el) 2017-03-15
AP2012006331A0 (en) 2012-06-30
SI2749282T1 (sl) 2017-12-29
US8754087B2 (en) 2014-06-17
UY33119A (es) 2011-07-29
WO2011084733A1 (en) 2011-07-14
SI2515900T1 (sl) 2015-07-31
AP3536A (en) 2016-01-13
BR112012015499A2 (pt) 2016-05-03
UA109887C2 (uk) 2015-10-26
EP2749282B1 (en) 2017-08-09
CN104147010A (zh) 2014-11-19
JP5723889B2 (ja) 2015-05-27

Similar Documents

Publication Publication Date Title
MX2012007052A (es) Metodo para tratar fibrilacion atrial.
CA2883751C (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
ECSP12012002A (es) Compuesto heterocíclico conteniendo nitrógeno y fungicida para el uso en agricultura y jardinería
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
PH12017501939B1 (en) 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
PH12018500253A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX384527B (es) Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
EP4140487A8 (en) Combination therapy for treating cancer
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2010028173A3 (en) Method of treating atrial fibrillation
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
MX335951B (es) Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades.
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2022012001A (es) Tratamiento preventivo de la migra?a.
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
WO2014100679A8 (en) Stimulation and enhancement of regeneration of tissues
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof